Cargando…

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice

INTRODUCTION: Limited data are available on the durability and effectiveness of maraviroc in routine clinical practice. We assessed the durability of maraviroc-containing regimens during a 30-month period, as well as their immunovirological and clinical efficacy, according to viral tropism in treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potard, Valérie, Reynes, Jacques, Ferry, Tristan, Aubin, Céline, Finkielsztejn, Laurent, Yazdanpanah, Yazdan, Costagliola, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695083/ https://www.ncbi.nlm.nih.gov/pubmed/26714012 http://dx.doi.org/10.1371/journal.pone.0144746

Ejemplares similares

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey
por: De Luca, Andrea, et al.
Publicado: (2019)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort
por: Cuzin, L, et al.
Publicado: (2010)

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis
por: Potard, Valérie, et al.
Publicado: (2014)

Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
por: Potard, Valérie, et al.
Publicado: (2018)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
por: Ilomuanya, Margaret O., et al.
Publicado: (2020)

Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART
por: Rusconi, S, et al.
Publicado: (2010)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
por: Reuter, S, et al.
Publicado: (2010)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness
por: Yazdanpanah, Yazdan, et al.
Publicado: (2010)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Durability of Sustained Virologic Response in Chronic Hepatitis C
por: Uyanikoglu, Ahmet, et al.
Publicado: (2013)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
por: Férir, Geoffrey, et al.
Publicado: (2011)

Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects
por: Giacomelli, Andrea, et al.
Publicado: (2019)

Two‐drug antiretroviral regimens: an assessment of virologic response and durability among treatment‐experienced persons living with HIV in the OPERA(®) Observational Database
por: Pierone, Gerald, et al.
Publicado: (2019)

First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN
por: Heera, Jayvant, et al.
Publicado: (2014)

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study
por: Rossetti, Barbara, et al.
Publicado: (2019)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
por: Larru, Beatriz, et al.
Publicado: (2007)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
por: Ferrer, Pablo, et al.
Publicado: (2020)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
por: Scaglione, Vincenzo, et al.
Publicado: (2020)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017
por: Castry, Mathieu, et al.
Publicado: (2021)

Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
por: Rhee, Soo-Yon, et al.
Publicado: (2017)

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
por: Sáez-Cirión, Asier, et al.
Publicado: (2013)

A Review of the Virological Efficacy of the 4 World Health Organization–Recommended Tenofovir-Containing Regimens for Initial HIV Therapy
por: Tang, Michele W., et al.
Publicado: (2012)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Immunologic impact of maraviroc in clinical practice of a university hospital
por: Paniagua, S Plata, et al.
Publicado: (2010)

Incidence of ischemic cardiovascular events in the maraviroc clinical development program
por: Portsmouth, S, et al.
Publicado: (2010)

Maraviroc: a review of its use in HIV infection and beyond
por: Woollard, Shawna M, et al.
Publicado: (2015)

Maraviroc-Mediated Lung Protection following Trauma-Hemorrhagic Shock
por: Liu, Fu-Chao, et al.
Publicado: (2016)

Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France
por: Pialoux, Gilles, et al.
Publicado: (2015)

Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination
por: Herrero-Fernández, Inés, et al.
Publicado: (2018)

Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study
por: Capetti, Amedeo Ferdinando, et al.
Publicado: (2017)

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus
por: Sax, Paul E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ijup561j6t0o2mir26hs9h8c52